上市公司花了1.25亿元研发的仿制药,上市申请被否!仿制对象已“翻车”:因安全性问题在欧美市场退市

每日经济新闻
Oct 14, 2025

炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会!   上市公司花了1.25亿元研发的仿制药,上市申请被否!仿制对象已“翻车”:因安全性问题在欧美市场退市,所有相关临床试验被暂停   10月13上市公司花了1.25亿元研发的仿制药,上市申请被否!仿制对象已“翻车”:因安全性问题在欧美市场退市,所有相关临床试验被暂停日,复旦张江(688505.SH)公告称,公司全资子公司泰州...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10